Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AUTLNASDAQ:ERYPNASDAQ:MGTXNASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAUTLAutolus Therapeutics$1.91+8.9%$1.41$1.11▼$5.00$504.34M1.771.51 million shs1.72 million shsERYPERYTECH Pharma$3.10$4.66$0.30▼$1.47$105.77M2.6993,510 shsN/AMGTXMeiraGTx$5.46+6.5%$5.81$3.85▼$8.75$437.83M1.3366,453 shs320,002 shsTECXTectonic Therapeutic$22.95+6.7%$19.37$13.70▼$61.07$428.68M3.44174,144 shs176,266 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAUTLAutolus Therapeutics0.00%+12.99%+28.89%-0.57%-58.47%ERYPERYTECH Pharma0.00%0.00%0.00%0.00%0.00%MGTXMeiraGTx0.00%+1.57%-28.55%-20.06%+5.71%TECXTectonic Therapeutic0.00%-0.65%-1.10%-8.12%+2,150,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAUTLAutolus Therapeutics2.7169 of 5 stars3.51.00.00.03.43.30.6ERYPERYTECH PharmaN/AN/AN/AN/AN/AN/AN/AN/AMGTXMeiraGTx4.5588 of 5 stars3.52.00.04.82.92.51.9TECXTectonic Therapeutic2.9413 of 5 stars3.61.00.00.02.35.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAUTLAutolus Therapeutics 3.00Buy$9.32389.24% UpsideERYPERYTECH Pharma 0.00N/AN/AN/AMGTXMeiraGTx 3.00Buy$24.00339.96% UpsideTECXTectonic Therapeutic 3.14Buy$79.20245.17% UpsideCurrent Analyst Ratings BreakdownLatest ERYP, AUTL, MGTX, and TECX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025TECXTectonic TherapeuticMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$51.00 ➝ $85.005/14/2025MGTXMeiraGTxChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$38.00 ➝ $35.004/21/2025TECXTectonic TherapeuticMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$51.004/10/2025AUTLAutolus TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.004/1/2025AUTLAutolus TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/21/2025AUTLAutolus TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$8.00 ➝ $6.003/21/2025TECXTectonic TherapeuticWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$112.00 ➝ $101.003/17/2025MGTXMeiraGTxRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$11.00 ➝ $13.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAUTLAutolus Therapeutics$9.01M56.26N/AN/A$0.64 per share2.98ERYPERYTECH Pharma$32.66M3.24N/AN/A$0.80 per share3.88MGTXMeiraGTx$34.51M12.70N/AN/A$2.17 per share2.51TECXTectonic TherapeuticN/AN/AN/AN/A$2.13 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAUTLAutolus Therapeutics-$208.38M-$0.88N/AN/AN/AN/A-63.65%-36.54%8/14/2025 (Estimated)ERYPERYTECH Pharma-$240KN/A0.00∞N/AN/AN/AN/AN/AMGTXMeiraGTx-$84.03M-$2.32N/A14.360.37-633.05%-146.38%-53.05%8/11/2025 (Estimated)TECXTectonic Therapeutic$12.16M-$7.31N/AN/AN/AN/A-35.53%-31.97%8/13/2025 (Estimated)Latest ERYP, AUTL, MGTX, and TECX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MGTXMeiraGTx-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million5/8/2025Q1 2025AUTLAutolus Therapeutics-$0.24-$0.26-$0.02-$0.26$1.59 million$8.98 million5/8/2025Q1 2025TECXTectonic Therapeutic-$1.10-$0.93+$0.17-$0.93N/AN/A3/20/2025Q4 2024AUTLAutolus Therapeutics-$0.21-$0.09+$0.12-$0.09$2.98 million$0.03 million3/20/2025Q4 2024TECXTectonic Therapeutic-$1.39-$0.84+$0.55-$0.84N/AN/A3/13/2025Q4 2024MGTXMeiraGTx-$0.48-$0.50-$0.02-$0.50$1.50 million$21.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAUTLAutolus TherapeuticsN/AN/AN/AN/AN/AERYPERYTECH PharmaN/AN/AN/AN/AN/AMGTXMeiraGTxN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAUTLAutolus TherapeuticsN/A13.6913.69ERYPERYTECH Pharma0.323.653.65MGTXMeiraGTx0.862.342.34TECXTectonic TherapeuticN/A9.399.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAUTLAutolus Therapeutics72.83%ERYPERYTECH Pharma1.09%MGTXMeiraGTx67.48%TECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipAUTLAutolus Therapeutics25.70%ERYPERYTECH Pharma1.94%MGTXMeiraGTx7.50%TECXTectonic Therapeutic38.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAUTLAutolus Therapeutics330266.14 million197.71 millionOptionableERYPERYTECH Pharma4934.12 million33.46 millionNot OptionableMGTXMeiraGTx30080.37 million71.59 millionOptionableTECXTectonic Therapeutic12018.67 million13.40 millionN/AERYP, AUTL, MGTX, and TECX HeadlinesRecent News About These CompaniesTectonic Therapeutic Reports Q1 2025 Financial ResultsMay 31 at 12:07 AM | tipranks.comWoodline Partners LP Has $6.01 Million Holdings in Tectonic Therapeutic (NASDAQ:TECX)May 26, 2025 | marketbeat.com29,702 Shares in Tectonic Therapeutic (NASDAQ:TECX) Purchased by Jane Street Group LLCMay 22, 2025 | marketbeat.comPromising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45May 22, 2025 | tipranks.comSoleus Capital Management L.P. Makes New Investment in Tectonic Therapeutic (NASDAQ:TECX)May 21, 2025 | marketbeat.comTectonic Therapeutic Announces Phase 1b Trial ResultsMay 19, 2025 | tipranks.comPromising Phase 1b Results and Favorable Safety Profile Justify Buy Rating for Tectonic TherapeuticMay 19, 2025 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Amgen (AMGN)May 17, 2025 | theglobeandmail.comTectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in ...May 17, 2025 | gurufocus.comTectonic Therapeutic Reports Positive Phase 1b Results for TX45 in Group 2 Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection FractionMay 17, 2025 | quiverquant.comTectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart FailureMay 17, 2025 | investing.comTectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025May 17, 2025 | globenewswire.comParadigm Biocapital Advisors LP Takes $22.40 Million Position in Tectonic Therapeutic (NASDAQ:TECX)May 16, 2025 | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Receives Consensus Recommendation of "Buy" from AnalystsMay 16, 2025 | marketbeat.comWall Street Analysts See a 258.52% Upside in Tectonic Therapeutic, Inc. (TECX): Can the Stock Really Move This High?May 13, 2025 | zacks.comTectonic Therapeutic (NASDAQ:TECX) Announces Earnings Results, Beats Expectations By $0.17 EPSMay 12, 2025 | marketbeat.comFarallon Capital Management LLC Boosts Holdings in Tectonic Therapeutic (NASDAQ:TECX)May 11, 2025 | marketbeat.comBalyasny Asset Management L.P. Has $11.40 Million Stock Holdings in Tectonic Therapeutic (NASDAQ:TECX)May 11, 2025 | marketbeat.comTectonic Therapeutic (NASDAQ:TECX) Shares Purchased by Barclays PLCMay 9, 2025 | marketbeat.comPromising Potential of Tectonic Therapeutic’s TX45: Buy Rating Supported by Positive Phase Ib Trial Results and Phase II ProspectsMay 8, 2025 | tipranks.comTectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business HighlightsMay 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeERYP, AUTL, MGTX, and TECX Company DescriptionsAutolus Therapeutics NASDAQ:AUTL$1.90 +0.16 (+8.86%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.ERYTECH Pharma NASDAQ:ERYPERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.MeiraGTx NASDAQ:MGTX$5.46 +0.34 (+6.54%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.Tectonic Therapeutic NASDAQ:TECX$22.94 +1.44 (+6.67%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Ackman Takes a Swing at Amazon — Should You? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
